Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics|
Maitland-van der Zee, A.
van Kuilenburg, A.
van Schaik, R.
|Citation:||Pharmacogenomics, 2011; 12(1):113-124|
|Laurent Becquemont, Ana Alfirevic, Ursula Amstutz, Hiltrud Brauch, Evelyne Jacqz-Aigrain, Pierre Laurent-Puig, Miguel A Molina, Mikko Niemi, Matthias Schwab, Andrew A Somogyi, Eric Thervet, Anke-Hilse Maitland-van der Zee, André BP van Kuilenburg, Ron HN van Schaik, Céline Verstuyft, Mia Wadelius, Ann K Daly|
|Abstract:||The present article summarizes the discussions of the 3rd European Science Foundation-University of Barcelona (ESF-UB) Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics, which was held in June 2010 in Spain. It was focused on practical applications in routine medical practice. We provide practical recommendations for ten different clinical situations, that have either been approved or not approved by regulatory agencies. We propose some comments that might accompany the results of these tests, indicating the best drug and doses to be prescribed. The discussed examples include KRAS, cetuximab, panitumumab, EGFR-gefitinib, CYP2D6-tamoxifen, TPMT-azathioprine-6-mercaptopurine, VKORC1/CYP2C9-warfarin, CYP2C19-clopidogrel, HLA-B*5701-abacavir, HLA-B*5701-flucloxacillin, SLCO1B1-statins and CYP3A5-tacrolimus. We hope that these practical recommendations will help physicians, biologists, scientists and other healthcare professionals to prescribe, perform and interpret these genetic tests.|
|Keywords:||adverse drug reaction; azathioprine; cetuximab; clopidogrel; gefitinib; genetic testing; pharmacogenetics; statins; tacrolimus; tamoxifen; warfarin|
|Rights:||© 2011 Future Medicine Ltd|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.